Table 1.

Characteristics of the study group

Patients	N = 86
Sex	n	%
Male	55	64
Female	31	36
Type of HSCT	n	%
MUD	59	69
HLA ID SIB	18	21
HLA MM REL	9	10
Source of stem cells	n	%
Peripheral blood	71	83
– after T cell depletion in vitro	8	9
Bone marrow	15	17
Diagnosis	n	%
Malignant (M)	64	74
Acute lymphoblastic leukaemia (ALL)	33	38
Acute myeloblastic leukaemia (AML)	17	20
Solid tumours (NBL, WT, PNET)	6	7
Chronic myeloid leukaemia (CML)	1	1
Hodgkin lymphoma (HL)	2	2
Non-Hodgkin lymphoma (NHL)	1	1
Myelodysplastic syndrome (MDS)	3	3
Xanthogranuloma juvenile	1	1
Non malignant (NM)	22	26
Severe aplastic anaemia (SAA)	4	5
Metabolic diseases (WM)	1	1
Immune deficiencies (ID*)	17	20
Conditionning
Myeloablative (MA)	50	58
Reduced-intensity conditioning (RIC)	24	28
Non-myeloablative (NMA)	8	10
None	4	4
Graft versus host disease (GvHD) prophylaxis
ATG	50	58
CAMPATH	13	15
None	22	26
ATG and CAMPATH	1	1

HLA ID SIB – HLA identical sibling; MUD – matched unrelated donor; HLA MM REL – HLA mismatched related donor; NBL – neuroblastoma; WT – Wilms tumour; PNET – primitive neuroectodermal tumour